Lipocine Inc.

Lipocine Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Lipocine Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. The company develops drugs based on Hydroance, a drug delivery technology. It primarily focuses on developing oral versions of several hormones for use in men and women health. The company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. It also offers custom drugs for pharmaceutical/biotechnology companies. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Company Details

Employees
25
Founded
-
Address
675 S Arapeen Dr, Salt Lake City,utah 84108,united States
Phone
8019947383
Email
ad****@****ine.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Salt Lake City, Utah
Looking for a particular Lipocine Inc. employee's phone or email?

Lipocine Inc. Questions

News

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PR Newswire

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) PR Newswire

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 - Yahoo Finance

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 Yahoo Finance

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference - PR Newswire

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference PR Newswire

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada PR Newswire

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - PR Newswire

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil PR Newswire

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - PR Newswire

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology PR Newswire

Lipocine Announces FDA Labeling Changes for Testosterone Products - PR Newswire

Lipocine Announces FDA Labeling Changes for Testosterone Products PR Newswire

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PR Newswire

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 PR Newswire

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - PR Newswire

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 PR Newswire

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - PR Newswire

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase PR Newswire

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - PR Newswire

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 PR Newswire

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - PR Newswire

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 PR Newswire

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - PR Newswire

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 PR Newswire

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries PR Newswire

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PR Newswire

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 PR Newswire

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PR Newswire

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 PR Newswire

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis PR Newswire

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 - PR Newswire

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 PR Newswire

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - PR Newswire

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study - PR Newswire

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals - PR Newswire

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals PR Newswire

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021 - PR Newswire

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021 PR Newswire

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - Barchart.com

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) Barchart.com

Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement - CNN

Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement CNN

Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO - CNN

Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO CNN

Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model - CNN

Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model CNN

Lipocine Announces FDA Advisory Committee Meeting for TLANDO™ - GlobeNewswire

Lipocine Announces FDA Advisory Committee Meeting for TLANDO™ GlobeNewswire

Top Lipocine Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant